DCM
LCTX icon

DAFNA Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,511,374
Closed -$1.13M 78
2025
Q1
$1.13M Hold
2,511,374
0.32% 52
2024
Q4
$1.26M Buy
2,511,374
+1,160,666
+86% +$583K 0.32% 53
2024
Q3
$1.22M Hold
1,350,708
0.29% 58
2024
Q2
$1.35M Sell
1,350,708
-15,600
-1% -$15.6K 0.32% 54
2024
Q1
$2.02M Buy
+1,366,308
New +$2.02M 0.46% 45
2023
Q3
Sell
-140,000
Closed -$197K 76
2023
Q2
$197K Hold
140,000
0.05% 71
2023
Q1
$210K Hold
140,000
0.06% 68
2022
Q4
$164K Hold
140,000
0.05% 76
2022
Q3
$158K Hold
140,000
0.04% 84
2022
Q2
$221K Hold
140,000
0.06% 86
2022
Q1
$216K Buy
140,000
+60,000
+75% +$92.6K 0.06% 90
2021
Q4
$196K Buy
+80,000
New +$196K 0.05% 87
2021
Q2
Sell
-75,400
Closed -$177K 89
2021
Q1
$177K Sell
75,400
-4,600
-6% -$10.8K 0.04% 87
2020
Q4
$141K Sell
80,000
-15,000
-16% -$26.4K 0.04% 74
2020
Q3
$89K Hold
95,000
0.03% 79
2020
Q2
$83K Hold
95,000
0.02% 86
2020
Q1
$79K Hold
95,000
0.03% 79
2019
Q4
$85K Hold
95,000
0.03% 80
2019
Q3
$93K Hold
95,000
0.04% 86
2019
Q2
$105K Hold
95,000
0.04% 82
2019
Q1
$124K Sell
95,000
-5,000
-5% -$6.53K 0.05% 76
2018
Q4
$91K Hold
100,000
0.05% 79
2018
Q3
$235K Sell
100,000
-81,600
-45% -$192K 0.1% 71
2018
Q2
$374K Hold
181,600
0.18% 64
2018
Q1
$489K Sell
181,600
-93,400
-34% -$252K 0.24% 60
2017
Q4
$591K Buy
+275,000
New +$591K 0.32% 58